Study wrapper · #606
Hexarelin Protects Rodent Pancreatic Β-Cells Function from Cytotoxic Effects of Streptozotocin Involving Mitochondrial Signalling Pathways In Vivo and In Vitro.
Editor's note
Combining cell-culture and rat experiments, researchers reported that hexarelin, a synthetic ghrelin analog, reduced streptozotocin toxicity to insulin-producing pancreatic beta-cells. In MIN6 beta-cells, hexarelin improved viability, limited mitochondrial damage and excess superoxide, and lowered apoptosis markers (cleaved caspase-3 and -9, Bax/Bcl-2 ratio). In a rat type-1-diabetes model, hexarelin was associated with higher plasma insulin, better-preserved islet structure, and reduced apoptotic signaling. Mitochondrial pathways are proposed as the mechanism. The dual approach adds coherence, but this remains a chemically induced beta-cell injury model with surrogate endpoints. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Researchers studied hexarelin, a lab-made peptide similar to the hormone ghrelin, to see whether it could protect the pancreas's insulin-making beta-cells from a toxic chemical (streptozotocin). In lab-grown mouse beta-cells, hexarelin improved survival, limited damage to the cells' energy structures (mitochondria), and reduced signals of cell death. In rats with type-1-diabetes-like injury, hexarelin was linked to higher insulin levels, better-preserved pancreatic islet structure, and less cell-death signaling. The authors suggest hexarelin protects beta-cells by acting on mitochondrial pathways. The abstract reports no adverse events. These are preclinical findings in cells and rats; human research would be needed before drawing any clinical conclusions.